ReviewRole of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: A systematic review and meta-analysis
Introduction
Differentiating glioma recurrence from radiation necrosis remains a great challenge. The two entities have totally different prognosis, however often share the same symptoms and the same features in conventional morphologic imaging like computerized tomography (CT) and magnetic resonance imaging (MRI) [1]. To solve the problem, numerous innovative imaging technologies focusing on metabolism or blood flow have been introduced, like positron-emission tomography (PET) with different tracers, single photon emission computed tomography (SPECT), and some advanced MRI techniques (diffusion-weighted imaging [DWI], dynamic susceptibility contrast-enhanced perfusion imaging, and magnetic resonance spectroscopy [MRS], etc.) [1], [2], [3], [4]. They are believed to contribute a lot to the distinction and the clinical decision-making in the absence of histopathologic confirmation. Some of them are very promising with high sensitivity (SEN) and specificity (SPE). However, MRS might be the most suited noninvasive tool when a new enhancing lesion is first identified since it is an adjunct to MRI and it only requires the imaging time is extended for 15–30 min [5].
MRS provides information about metabolic tissue composition, advanced spectroscopic methods have been used to quantify markers of tumor metabolism (e.g. glucose), membrane turnover and proliferation (e.g. choline [Cho]), energy homoeostasis (e.g. creatine [Cr]), intact glioneural structures (e.g. N-acetyl-aspartate [NAA]), and necrosis (e.g. lactate [Lac] or lipids) [5]. Results are usually expressed as ratios between cerebral metabolites, rather than absolute concentrations. Numerous studies have evaluated the diagnostic role of MRS for distinguishing glioma recurrence from radiation necrosis. However, the sample size in each study is relatively small, which may compromise the credibility of results. Thus, we performed the present meta-analysis to evaluate the diagnostic accuracy of MRS for differentiating recurrent glioma from radiation necrosis.
Section snippets
Search strategy
A comprehensive computer literature search of the PubMed, Embase and Chinese Biomedical databases was conducted to find relevant published articles (up to May 4, 2014). The search terms were as follows: (“Magnetic resonance spectroscopy” or “MR spectroscopy” or “MRS”) AND (glioma or brain neoplasm) AND recurrence. The equivalent Chinese terms were used in the Chinese databases. Additionally, the reference lists of all retrieved articles were checked for other eligible reports that have not been
Study selection and characteristics
The study selection process is detailed in Fig. 1. Eighteen articles [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30] comprising a total sample size of 455 patients (447 lesions) with suspected glioma recurrence after radiotherapy, met all inclusion and exclusion criteria, and were included in our meta-analysis. The characteristics of the included studies are presented in Table 1.
Fifteen studies were retrospective cohort studies, and
Discussion
When new contrast-enhancing lesions are discovered at or near the site of previously treated glioma, contrast-enhanced anatomic MRI usually can’t reliably discriminate between radiation change and recurrent tumor, which requires new imaging techniques [1], [2], [3], [4]. MRS is a non-invasive and non-ionizing technique based on fundamental nuclear magnetic resonance principles, which is used to gain metabolic information from tissues of interest. It can detect a large number of endogenous
Conclusion
This meta-analysis provides evidence that MRS alone has moderate diagnostic performance in differentiating glioma recurrence from radiation necrosis using metabolite ratios like Cho/Cr and Cho/NAA ratios. It is strongly recommended that MRS should combine other advanced imaging technologies to improve diagnostic accuracy. This article also underlines the importance of implementing multimodal imaging trials and multicentre trials in the future. In the interpretation of our results, the
Conflicts of interest
The authors declare that they have no conflict of interest.
References (32)
- et al.
Challenges with the diagnosis and treatment of cerebral radiation necrosis
Int J Radiat Oncol Biol Phys
(2013) - et al.
Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis
J Clin Neurosci
(2012) - et al.
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
Lancet Neurol
(2010) - et al.
The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed
J Clin Epidemiol
(2005) - et al.
Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease
Acad Radiol
(2013) - et al.
MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury
Acad Radiol
(2011) - et al.
Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-d-glucose positron emission tomography for detection of recurrence or grade increase in gliomas
J Clin Neurosci
(2010) - et al.
Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging
Int J Radiat Oncol Biol Phys
(2007) - et al.
The diagnostic odds ratio: a single indicator of test performance
J Clin Epidemiol
(2003) - et al.
Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities
J Neurooncol
(2009)
Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies
Neuro Oncol
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Ann Intern Med
Conducting systematic reviews of diagnostic studies: didactic guidelines
BMC Med Res Methodol
Meta-DiSc: a software for meta-analysis of test accuracy data
BMC Med Res Methodol
Measuring inconsistency in meta-analyses
Br Med J
Systematic reviews of diagnostic test accuracy
Ann Intern Med
Cited by (116)
Post-treatment imaging of gliomas: challenging the existing dogmas
2024, Clinical RadiologyMRI-based contrast clearance analysis shows high differentiation accuracy between radiation-induced reactions and progressive disease after cranial radiotherapy
2022, ESMO OpenCitation Excerpt :However, the meta-analysis yielded very variable cutoff values for an optimal discrimination between both conditions due to heterogeneous methodological designs.23,24 Another approach is the use of magnetic resonance spectroscopy23,25,26 for which Anbarloui et al.27 described a diagnostic accuracy of 81% validated on 33 patients. Akbari et al.28 used machine learning with multiparametric MRI and predicted PsP or PD with an overall accuracy of 75% in an interinstitutional validation cohort with 20 patients.
Advanced magnetic resonance imaging of brain tumours
2022, Handbook of Neuro-Oncology NeuroimagingNeuroimaging issues in assessing glioma response to brain tumour therapy
2022, Handbook of Neuro-Oncology Neuroimaging
- 1
These authors are first authors and they are contributed equally to this work.